Four ways to increase rare disease drug development success
There are more than 7,000 identified rare diseases today, 71.9% of which are genetic. And only around 5% of rare diseases have treatments. Development is complex and presents specific challenges. For example, many rare disease patients are children, since nearly 70% of rare diseases are exclusively pediatric-onset. The patient pool is often very limited for any one disease, and patients are often geographically dispersed, highlighting the importance of selecting a development partner with strong patient recruitment and global operational capabilities.
In this playbook, Parexel shares insights on maximizing the chances of success in rare disease drug development, providing our perspectives on four of the most significant challenges:
- Easing trial burdens on sites, and enhancing the clinical staff experience
- Ensuring that pediatric trials are ethical and feasible for patients and families
- Getting to market faster and stronger with natural history studies and real-world evidence
- Learning from past successes and failures in orphan indications
We hope you find these articles helpful on your journey.
Related Insights
Blog
Decoding FDA’s new flexible CMC requirements for cell and gene therapies
Jan 26, 2026
Article
Implementing patient-centric decentralized clinical trials in Japan
Mar 16, 2023
Blog
Innovative modeling method could speed patient access to critical IO therapies
Jan 4, 2023
Blog
The New Frontier of Innovative Therapies: Navigating What's Next
Jan 12, 2023
Playbook
Are you using real-world evidence?
Feb 1, 2023
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Whitepaper
Optimizing Biosensor-based Trials
Feb 1, 2023
Webinar
How to navigate China’s regulatory environment
Feb 15, 2023
Playbook
Insights from the 2022 R&D Innovation Survey
Feb 17, 2023
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Playbook
Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success
Mar 28, 2023
Blog
New CNS Franchise Leader brings experience from pharma and as a clinician and researcher
Nov 14, 2022
Related Insights
Blog
Decoding FDA’s new flexible CMC requirements for cell and gene therapies
Jan 26, 2026
Article
Implementing patient-centric decentralized clinical trials in Japan
Mar 16, 2023
Blog
Innovative modeling method could speed patient access to critical IO therapies
Jan 4, 2023
Blog
The New Frontier of Innovative Therapies: Navigating What's Next
Jan 12, 2023
Playbook
Are you using real-world evidence?
Feb 1, 2023
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Whitepaper
Optimizing Biosensor-based Trials
Feb 1, 2023
Webinar
How to navigate China’s regulatory environment
Feb 15, 2023
Playbook
Insights from the 2022 R&D Innovation Survey
Feb 17, 2023
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Playbook
Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success
Mar 28, 2023
Blog
New CNS Franchise Leader brings experience from pharma and as a clinician and researcher
Nov 14, 2022